ATLANPOLE - Biothérapies

Thinking up tomorrow's medicine

Feeds

News

IN2LifeSciences project concludes successful third round

logo in2lifesciences

[Press release] On February 1, the fourth and final call for incentives has opened, offering SMEs the chance to speed up their innovation. Life Sciences SMEs are invited to apply until May 4, 2014. A total of 164 incentives have been granted during the first three calls; 53 Collaboration, 29 Insight, 82 Meet and Greet. SMEs that wish to take part in the project can contact their Regional Access Broker or fill out an online application form.

A new member joins in the cluster: Korilog

KORILOG is a publisher of scientific software for sequence data analysis. The company offers a range of software based on KLAST, the new high-performance sequence similarity search technology created by Korilog and the Rennes INRIA1-IRISA2 research center. Through the network of Atlanpole Biotherapies, Korilog wants to accelerate its development by taking part in projects with the network members, both private and academic.

Two DHU projects certified in Nantes

To better coordinate care, teaching and research, to strengthen relations between hospital and university, to share innovation more efficiently... These are some of the objectives of the two university hospital departments (DHU), which an international jury selected in Nantes.

AAA receives orphan drug designation from FDA and EMA for Gallium-68 DOTATATE

Advanced Accelerator Applications

Advanced Accelerator Applications announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE. The orphan drug designation has been granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic agent for the management of Gastro-Entero- Pancreatic Neuroendocrine Tumors (GEP-NETs).

Creation of Horama

Horama

Horama is a biotechnology company specializing in the development of innovative gene therapy products for the treatment of retinopathies, serious and “orphan” diseases, resulting in loss of visual acuity or blindness.

Valneva: Aeras Initiates Phase II Clinical T rial of A Tuberculosis Vaccine Candidate U sing IC31 ® A djuvant

Valneva

[Press release] European Biotech company Valneva is pleased to distribute the following press release issued by Aeras about the initiation of a Phase II randomized clinical trial for their tuberculosis (TB) vaccine candidate Aeras-404 using Valneva's IC31® proprietary adjuvant.

Cédric Le May was awarded the Daniel Steinberg prize of the best scientific publication

Crédits photo : Presse Océan - Olivier Lanrivain

Researcher at the thorax Institute, Cédric Le May was awarded the Daniel Steinberg prize of the best 2013 scientific publication.

Your news

Events

April 29th-30th, 2014 : register now for "Cancer Vaccines and immunomodulation"

This two-day international workshop features presenta¬tions by leading actors in the field of anti-tumor immunity from academia, industry and biotech companies providing a platform for scientific discussion and launching of colla-borative projects.

April 29 : STERN Forum in Stuttgart

The Stern-Forum: "Innovation and Biomaterials" serves as a pathfinder for entrepreneurs and researchers in order to establish upcoming business contacts and collaborations. The event, which will be held in English, is organised in the context of the two EU-projects, nameley Biomat-IN and IN2LifeSciences. This will afford you the opportunity to engage with regional biotechnology, medical technology and other life sciences companies.

April 9th: informational web conference on UbiStart 2014

You are a French company in the healthcare industry and initiating an innovative project, you want to accelerate your international development by partnering with professionals whose expertise is recognized. On July 11th and 12th, Ubistart, which will be a unique opportunity to create partnerships with North American innovative start-up companies in the health sector, will take place in New York. Attend the free information webinar on April 9th.

April 28th to may 2th : Atlanpole Biotherapies at Bio IT Conference & Expo

BioIT World

Atlanpole Biotherapies, Korilog and Bakasable (two of our companies) will attend this major international conference about the application of informatics, IT and computer science in biomedical research and drug discovery.

June 23 to 26th 2014 : Atlanpole Biotherapies at BIO San Diego

An Atlanpole Biotherapies delegation will attend this major international convention on biotechnologies which is taking place in San Diego from the 23rd to the 26th of June.

International Cancer Cluster Showcase 2014 - Bio San Diego

International Cancer Cluster Showcase will take place June 22nd, 2014 - Bio San Diego

July 2 to 4 : EORS 2014 meeting in Nantes

Organised by the European Orthopaedic Research Society, the EORS 2014 meeting will focus on the following special topics: the mechanisms of osteoinduction, osteoimmunology and bone tumors, transferring innovation to clinical practice. 300 people are expected at this conference that offers workshops and presentations by renowned researchers and surgeons.

Our events

The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation

 

Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005). 

Atlanpole UK

Annuaire